IDEAYA Biosciences, Inc. (IDYA)
| Market Cap | 2.53B +49.0% |
| Revenue (ttm) | 225.27M +3,118.1% |
| Net Income | -140.06M |
| EPS | -1.58 |
| Shares Out | 87.86M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,361,746 |
| Open | 27.79 |
| Previous Close | 27.60 |
| Day's Range | 27.37 - 29.54 |
| 52-Week Range | 20.50 - 39.28 |
| Beta | -0.05 |
| Analysts | Strong Buy |
| Price Target | 51.93 (+79.23%) |
| Earnings Date | May 5, 2026 |
About IDYA
IDEAYA Biosciences, Inc., a precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company offers Darovasertib, an oral, potent, and selective protein kinase, C (PKC) inhibitor for the treatment of uveal melanoma, ocular cancer, and is being evaluated in multiple clinical trials as monotherapy and in combination with crizotinib for metastatic, neoadjuvant, and adjuvant settings. The company also offers IDE849, a DLL3 antibody drug conjugate inhib... [Read more]
Financial Performance
In 2025, IDEAYA Biosciences's revenue was $218.71 million, an increase of 3024.43% compared to the previous year's $7.00 million. Losses were -$113.70 million, -58.58% less than in 2024.
Financial StatementsAnalyst Summary
According to 17 analysts, the average rating for IDYA stock is "Strong Buy." The 12-month stock price target is $51.93, which is an increase of 79.23% from the latest price.
News
IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
SOUTH SAN FRANCISCO, Calif., June 10, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA) today announced the closing of its underwritten public offering of 7,222,225 shares of its common sto...
Ideaya Biosciences 5.56M share Spot Secondary priced at $27.00
JPMorgan, Jefferies, TD Cowen, UBS and Cantor Fitzgerald acted as joint book running managers for the offering.
IDEAYA Announces Pricing of $300 Million Offering of Common Stock and Pre-Funded Warrants
SOUTH SAN FRANCISCO, Calif., June 8, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA) today announced the pricing of an underwritten public offering of common stock and pre-funded warrants.
Ideaya Biosciences $300M Spot Secondary re-offered at $27.00
JPMorgan, Jefferies, TD Cowen, UBS and Cantor Fitzgerald are acting as joint book running managers for the offering.
Ideaya Biosciences announces $300M common stock offering
Ideaya Biosciences (IDYA) announced that it intends to offer and sell up to $300M of shares of its common stock and, in lieu of common stock, to offer and sell…
IDEAYA Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
SOUTH SAN FRANCISCO, Calif., June 8, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA) today announced that it intends to offer and sell up to $300.0 million of shares of its common stock a...
IDEAYA Biosciences Transcript: Jefferies Global Healthcare Conference 2026
Announced a new Roche collaboration for a pan-RAS/PRMT5 combo in MTAP deletion pancreatic cancer. Darovasertib showed strong phase III results in uveal melanoma, with expedited FDA review underway. Multiple late-stage trials and data updates, including DLL3 ADC and KAT6/7 inhibitor, are expected in the second half of the year.
Ideaya Biosciences announces IDE892 collaboration with Roche
Ideaya Biosciences (IDYA) announced it has entered into a clinical collaboration with Roche (RHHBY) to evaluate the efficacy and safety of IDE892 in combination with Roche’s RG6505, a pan-RAS inhibito...
IDEAYA Biosciences Announces Clinical Collaboration with Roche in MTAP-Deleted RAS-Mutant Pancreatic Cancer
IDEAYA entered into a clinical collaboration with Roche to evaluate IDE892, IDEAYA's potential best-in-class Phase 1 MTA-cooperative PRMT5 inhibitor, in combination with RG6505, Roche's Phase 1 pan-RA...
Ideaya Biosciences, Servier present data from Phase 2/3 OptimUM-02 trial
IDEAYA Biosciences (IDYA) and Servier presented complete data from the primary analysis of their registrational Phase 2/3 OptimUM-02 trial of darovasertib in combination with crizotinib in first line ...
IDEAYA Biosciences and Servier Provide Complete Data from Phase 2/3 Registrational OptimUM-02 Trial of the Darovasertib Combination in First Line HLA*A2:01 Negative Metastatic Uveal Melanoma in a Late-Breaking Oral Presentation at ASCO
Darovasertib combination resulted in a statistically significant and clinically meaningful improvement in median PFS vs. investigator's choice of therapy (ICT) – 6.9 months vs.
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., May 29, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeu...
Ideaya Biosciences management to meet with Cantor
Group Dinner Meeting with Management to be held in Chicago on June 1 hosted by Cantor.
IDEAYA Biosciences Transcript: 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA
Darovasertib showed strong efficacy in uveal melanoma, with robust PFS and response rates, and NDA submission is underway with expedited review. ADC and bispecific programs are advancing, with large data sets and early efficacy signals expected this year. MTAP and KAT6/7 programs target high-need cancers with novel mechanisms.
IDEAYA Biosciences Announces Participation at the 2026 Jefferies Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 26, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeu...
IDEAYA Biosciences Transcript: Stifel 2026 Targeted Oncology Virtual Forum
Positive clinical results for darovasertib in uveal melanoma support expedited NDA filing, with detailed efficacy and safety data to be presented at ASCO. Pipeline progress includes upcoming DLL3 ADC data, expansion into adjuvant/neoadjuvant settings, and strategic focus on PRMT5, MAT2A, and KAT6/7 programs.
IDEAYA Biosciences Transcript: Bank of America Global Healthcare Conference 2026
Focused on clinical distinction and procedural innovation, the company targets high-growth lateral surgery and imaging markets, achieving positive EBITDA and strong cash flow. Recent launches in robotics and international expansion support continued outsized growth and profitability.
Ideaya Biosciences price target lowered to $50 from $52 at Mizuho
Mizuho lowered the firm’s price target on Ideaya Biosciences (IDYA) to $50 from $52 and keeps an Outperform rating on the shares.
IDEAYA Biosciences Slides: Corporate presentation
IDEAYA Biosciences has posted slides in relation to its latest quarterly earnings report, which was published on May 5, 2026.
Ideaya Biosciences reports Q1 EPS ($1.11), consensus (98c)
Reports Q1 revenue $6.56M, consensus $5.04M. “This was a transformational quarter for IDEAYA, with positive topline results from the OptimUM-02 registrational trial in first line HLA*A2-negative metas...
IDEAYA Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update
Phase 2/3 registrational trial (OptimUM-02) of darovasertib combination met its primary endpoint; complete data will be provided in a late-breaking oral presentation at ASCO IDEAYA to initiate RTOR su...
IDEAYA Biosciences Earnings release: Q1 2026
IDEAYA Biosciences released its Q1 2026 earnings on May 5, 2026, summarizing the period's financial results.
IDEAYA Biosciences Quarterly report: Q1 2026
IDEAYA Biosciences has published its Q1 2026 quarterly earnings report on May 5, 2026.
IDEAYA Biosciences Proxy statement: Proxy filing
IDEAYA Biosciences filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.
Ideaya Biosciences announces darovasertib combination NDA to be reviewed by FDA
Ideaya Biosciences (IDYA) announced that the FDA has agreed to review its new drug application for darovasertib in combination with crizotinib for patients with first line HLA A2-negative metastatic u...